Protalix BioTherapeutics, Inc. (PLX)

From the record

Protalix BioTherapeutics, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2019-08-30); a warning not to rely on past financial statements (8-K item 4.02, the latest 2019-03-18) (its current reports).

From the record

Protalix BioTherapeutics, Inc.'s 10 filed years say what it did: revenue went from $9 million in fiscal 2016 to $53 million in fiscal 2025, up 21.4% a year; it rose in 6 of 9 years; the deepest fall was 39% from fiscal 2020 to fiscal 2021; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Protalix BioTherapeutics, Inc.'s diluted share count grew about 17.5% a year, and dividends and buybacks returned about 0% of its net income over 3 years (its filed statements). Its officers and directors filed 1 sale and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $101 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Protalix BioTherapeutics, Inc. lost about 14 cents for every dollar of shareholders' money, and gross profitability: its products earned about 31 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 41 cents per dollar of assets, and net share issuance: its share count shrank 3.1% over the year (the filed statements).

From the record

Protalix BioTherapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $53 million in fiscal 2025 ranks in the top 41% by size; a net margin of -12.5% ranks in the top 25%; revenue growth of 3.5% a year over the last 3 filed years ranks in the top 50% (its annual reports).

From the record

Protalix BioTherapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bashan, Dror (PRESIDENT AND CEO, as filed), filing under that title since 2019-07-02, 7.4 years (top 24% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 6.9 years (top 23%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Protalix BioTherapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $15 million against no long-term debt tagged leaves 17.8% of its assets as net cash, bottom 32% of its family; cash from operations less capital spending is -25.8% of revenue (top 28%); a gross margin of 48.8% (bottom 27%); research spending of 37.1% of revenue (bottom 28%) (its annual report).

From the record

Protalix BioTherapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 3.5% a year over the last three filed years against 21.4% over all 10, slowing (bottom 32% of its family); the newest year grew -1.2% (bottom 33%); research spending grew -12.6% a year (bottom 26%); capital spending grew 37.6% a year (top 9%) (its annual reports). Protalix BioTherapeutics, Inc. reported 2 product lines in fiscal 2025: Product at $52 million (98%), License and Service at $942 thousand (2%); 1 of 2 grew against the year before (its annual report).

From the record

Protalix BioTherapeutics, Inc.'s newest year against its own record: revenue of $53 million in fiscal 2025 came in 6.7% below the $57 million its prior three years' pace pointed to (bottom 35% of its family); net income of $7 million against a prior three-year average of $1 million (bottom 5%); a net margin of -12.5% against -4.4% before (bottom 30%) (its annual reports).